

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1522603> since 2016-06-24T09:22:43Z

*Published version:*

DOI:10.1016/j.atherosclerosis.2015.03.019

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

*This is a pre-copyedited, author-produced PDF of an article accepted for publication in Atherosclerosis following peer review. The version of record 2015 May;240(1):197-204. doi: 10.1016/j.atherosclerosis.2015.03.019. Epub 2015 Mar 16. is available online at:*  
*<http://www.sciencedirect.com/science/article/pii/S0021915015001793>*

# **High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis.**

Fabrizio D'Ascenzo MD, Enrico Cerrato MD, Andrea Calcagno MD, Walter Grosso Marra MD, Flavia Ballocca MD, Pierluigi Omedè MD, Antonio Montefusco MD, Simona Veglia MD, Umberto Barbero MD, Sebastiano Gili MD, Margherita Cannillo MD, Martina Pianelli MD, Elisa Mistretta MD, Alessio Raviola MD, Davide Salera MD, Domenica Garabello MD, Massimo Mancone MD, Vicente Estrada, MD, Javier Escaned, Daniela De Marie MD, MD, Phd, Antonio Abbate MD, Stefano Bonora Prof, Giuseppe Biondi Zoccai MD, Claudio Moretti MD, Phd and Fiorenzo Gaita, Prof.

Division of Cardiology Department of Medical Sciences, University of Turin, Italy; (FDA; EC; WGM; PO; AM; FB; UB; SG; MC; MP; EM; AR; DS; CM; FG); Division of Radiology, Turin (SV; DG) VCU Pauley Heart Center, Richmond, VA, USA (AA); Division of Infectious Disease, Amedeo di Savoia Hospital, Turin, Italy (AC, SB); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (GBZ); Policlinico Umberto I "Sapienza", University of Rome, Italy (MM); Hospital Clinicos San Carlos, Madrid, Spain (JE, VE); Division of Cardiology, Hospital Maria Vittoria (DDM); Cardiogroup.org collaborative group (FDA, EC, CM, JE, GBZ).

Corresponding author. Fabrizio D'Ascenzo, Division of Cardiology, Department of Internal Medicine, Turin. Email: [fabrizio.dascenzo@gmail.com](mailto:fabrizio.dascenzo@gmail.com). Website: [www.cardiogroup.org](http://www.cardiogroup.org)

## ABSTRACT.

**Introduction.** Asymptomatic patients with human immunodeficiency virus (HIV) infection are at increased risk of vascular disease. Whether asymptomatic HIV patients have increased prevalence or structural differences in coronary artery plaques is not clear.

**Methods.** Pubmed, Cochrane and Google Scholar were searched for articles evaluating asymptomatic HIV patients evaluated with coronary computed tomography. The prevalence of coronary stenosis (defined as >30% and > 50%), of calcified coronary plaques (CCP) viewed as more 'stable' plaques, and of non-calcified coronary plaques (NCP) viewed as more 'vulnerable' plaques were the end points of interest.

**Results.** 9 studies with 1229 HIV patients and 1029 controls were included. No significant differences were detected about baseline cardiovascular risk profile. The prevalence of significant coronary stenosis >30% or >50% did not differ between HIV+ and HIV- patients (42% [37-44] and 46% [35-52] with an Odds Ratio [OR] of 1.38 [0.86-2.20] for >30% stenosis) and (15% [9-21] and 14% [7-22] with an OR of 1.11 [0.81-1.52]), respectively. The prevalence of **calcified coronary plaques (CCP)** (31% [24-32] and 21% [14-30] with an OR of 1.17 [0.63-2.16]) also did not differ among HIV+ and HIV- patients. On the contrary rates of NCP were >3-fold higher in HIV-positive patients [58% (48-60) and 17% (14-27) with an OR of 3.26 (1.30-8.18)], with an inverse relationship with CD4 cell count at meta-regression (Beta -0.20 [-0.35-0.18], p 0.04).

**Conclusion.** Asymptomatic HIV patients present a similar burden of coronary stenosis **and** calcified coronary artery plaques but significantly higher rates of non-calcific coronary plaques at computed tomography. The association between HIV infection,

reduced CD4 cell counts and higher prevalence on non-calcific coronary artery plaques may shed light into the pathogenesis in HIV-associated coronary artery disease, **stressing the importance of primary prevention in this population.**

## **INTRODUCTION.**

Life expectancy of human immunodeficiency virus (HIV) patients dramatically increased thanks to highly active antiretroviral therapy (HAART)<sup>1</sup>. Physicians managing these patients are shifting towards a more global assessment of clinical conditions, with a particular attention of development of both clinical and subclinical cardiovascular disease<sup>2,3</sup>.

HIV patients, actually, are exposed for many years to the continuous interaction between traditional risk factors, coronary HIV infection, immune-mediated response and the still debated effect of HAART<sup>3,4</sup>.

In acute coronary syndrome (ACS) settings, this peculiar pathological pattern has led to a higher risk of coronary adverse events; several challenges have been identified in those patients, such as drug to drug interaction with new antiaggregants or statins and compliance to medications<sup>4</sup>.

Consequently, primary care is becoming crucial, both to prevent subclinical impairment of systolic and diastolic dysfunction<sup>5</sup> and to reduce number of cardiovascular adverse events<sup>3</sup>. Even subclinical atherosclerosis has been related with risk for cardiovascular events in the general population<sup>7,8</sup>, and particular for those presenting with non-calcified plaques due to a higher risk of rupture<sup>9</sup>. An increased use of coronary computed tomography (CCT) has been reported, both to measure coronary artery calcium (CAC) and to evaluate the prevalence and features of coronary plaques, in order to accurately address pharmacological and interventional strategies<sup>10-12</sup>.

Some studies have found a higher prevalence of subclinical atherosclerosis in HIV-positive patients<sup>13-15</sup> but the results are not consistent. Consequently we performed a systematic review to understand the prevalence and the peculiarities of coronary plaques in asymptomatic HIV-positive patients.

## **METHODS.**

The Cochrane Collaboration and Meta-analysis Of Observational Studies in Epidemiology (MOOSE)<sup>18</sup> was followed during elaboration of the present analysis.

### **Search strategy and study selection.**

Pertinent articles were searched in Medline, Cochrane Library, Biomed Central and Google Scholar in keeping with established methods<sup>16</sup> with Mesh strategy: ((coronary computed tomography) OR (CCT)) AND (hiv OR aids OR (human AND immunodeficiency AND virus)).

Two independent reviewers (F.DA, E.C.) first screened retrieved citations at the title and/or abstract level, with divergences resolved after consensus. If potentially pertinent, they were then appraised as complete reports according to the following explicit selection criteria. Studies were included if (i) investigating with CCT asymptomatic HIV and non HIV patients (ii) with more than 90% of patients treated with HAART. Exclusion criteria was (i) absence of non HIV controls.

### **Data extraction**

Two unblinded independent reviewers (G.B.-Z, F.DA, and E.C.) abstracted the following data on pre-specified forms: authors, journal, year of publication, location of the study group, baseline features, type and timing of antiretroviral therapy, and protocols of CCT. The prevalence of coronary stenosis (more than 30% and more than 50%), of

calcified coronary (CCP), of non-calcified coronary plaques (NCP) and of Coronary Artery Calcification Score (CAC) more than 0 were the end points of interest.

### **Internal validity and quality appraisal**

Unblinded independent reviewers (G.B.-Z, F.DA, and E.C.) evaluated quality of included studies on pre-specified forms. Modifying the MOOSE items to take into account the specific features of included studies,<sup>15-18</sup> we separately abstracted and appraised study design, setting, data source, as well as risk of analytical, selection, adjudication, detection, and attrition bias (expressed as low, moderate, or high risk of bias, as well as incomplete reporting leading to inability to ascertain the underlying risk of bias). For the quality assessment of the selected studies we used the Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis<sup>19</sup>.

### **Data analysis and synthesis**

Continuous variables are reported as mean (standard deviation) or median (range). Categorical variables are expressed as n/N (%). Statistical pooling was performed according to a random-effect model with generic inverse-variance weighting, computing risk estimates with 95% confidence intervals, using RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane Centre, and Copenhagen, Denmark). **Meta-regression analysis for the impact of traditional risk factors and HIV features on the primary end point was performed with random effect with Comprehensive Meta-Analysis after computation of the event rate.** All confidence intervals were of 95%). Standard hypothesis testing was set at the two-tailed 0.05 level.

## RESULTS.

217 studies were first screened at abstract level, and after evaluation 9 studies with 1229 HIV patients and 1029 controls were included<sup>20-28</sup>. (see Figure 1). **Eight studies out of nine were prospective: eight were performed in the USA and one in Europe.**

Baseline features of the included patients are reported in Table 1. HIV patients were more frequently of male gender, with higher rates of diabetes mellitus and of hypertension in the included studies, **but without significant differences.**

Concerning immunovirological variables these patients had been on HAART for 8.3 (8-9) years, with a CD4+ T lymphocyte cell count of 529/mm<sup>3</sup> (525-571) and a CD4+ nadir of 201 cells/mm<sup>3</sup> (181-257). 52% (51-53) have been exposed to Protease Inhibitors (PI), 94% (81-96) to nonnucleoside reverse-transcriptase inhibitors (NNRT) and 46% (43-47) to nucleoside reverse-transcriptase inhibitors (NRTIs).

In all studies, included patients were asymptomatic and only in the study of D'Abramo et al<sup>20</sup>, they were included after a positive ergometric test. Protocols and definitions of CCT were consistent among all studies (Table A, Appendix web only).

Prevalence of significant coronary stenosis (>30%) did not differ between HIV+ and HIV- patients [42% (37-44) and 46% (35-52) with an Odds Ratio (OR) of 1.38 (0.86-2.20)]. Similarly prevalence of coronary stenosis above 50% (15% 9-21 and 14% 7-22 with an OR of 1.11 [0.81-1.52]), of calcific coronary plaques (31% 24-32 and 21% 14-30 with an OR of



1.17 [0.63-2.16] and of CAC above zero (43% [39-48] and 46% [26-56] with an OR of 0.88 [0.43-1.79] did not differ among HIV+ and HIV- patients (see Figures 2 and 3). On the contrary rates of NCP were significantly higher in HIV-positive patients [58% (48-60) and 17% (14-27) with an OR of 3.26 (1-30-8.18)].

At meta-regression analysis for coronary stenosis above 30% active smoking habit increased the risk (Beta 0.02 0.01-0.03,  $p < 0.001$ ) in HIV+, Immunologic status and HAART therapy showed a neutral effect. Moreover, CD4 cell counts was inversely related to the risk of non-calcific plaque (the higher CD4 cell counts the lower the prevalence, Beta -0.20 -0.35-0.18  $p$  0.04). (see Tables 3 and 4, Figure 5).

At funnel plot analysis, low selection bias was noted (Figure A).

## DISCUSSION

This is the first paper reporting a pooled analysis of data about CCT scan in asymptomatic HIV patients. The main findings are: 1) HIV-infected patients present higher rates of NCP compared to similar cohorts of HIV-negative subjects 2) NCP prevalence and degree were positively associated with worse immunovirological parameters, suggesting that disease stage contributes to cardiovascular instability.

NCP represent an early stage of atherosclerosis, resulting to be more prone to rupture and thrombus formation compared than calcified ones, potentially leading to ACS. These observations were already reported in series of patients evaluated by CCT as well in ACS patients undergoing angiography followed by grayscale and radiofrequency intravascular ultrasonography (IVUS)<sup>30,31</sup> and were also consistent with pathological studies reporting that plaque more prone to rupture show a thin cap fibro atheroma and necrotic core with an overlying thin fibrous cap<sup>32,33</sup>.

Previous CCT studies reported a higher prevalence of NCP in intermediate-risk asymptomatic patients, especially in those with significantly higher level of C-reactive protein, cholesterol (total and low-density lipoprotein) as well as a trend for a higher prevalence of diabetes mellitus<sup>34</sup>. Our analysis includes a young population (median age of 47 years) with a low prevalence of diabetes and a moderate prevalence of hyperlipidemia (11% and 27% respectively). Despite these characteristics, the prevalence of NCP was 3-fold higher compared with similar Framingham-based score non-HIV population (58% vs. 17%) and comparable to the one reported in recent study<sup>35</sup> by Park et al (NCP rate = 56%).

We reported a CAC score value higher than zero in less than half of subjects. Even if CAC score of zero was associated with very low risk of cardiac events, NCP plaque cannot be detected on non-contrast cardiac scans, used to measure CAC levels. **Previous studies utilizing CCT to estimate the extent of coronary artery disease in HIV patients assessed only CAC by scoring without explore directly the lumen caliber or plaques burden<sup>36,37</sup>. Although the CAC scoring is a well defined marker for atherosclerotic lesions and cardiac event risk in non-HIV population, it may not provide a reliable valuation of early atherosclerosis in young HIV patients in whom calcifications are absent: our finding demonstrate that a significant proportion of patients with coronary atherosclerosis may be missed using only calcium score criterion. Thus we stressed the additional value of adopting CCT over CAC scoring alone for the assessment of coronary tree in young HIV-positive patients; since CCP probably reflects advanced stable atherosclerosis while identifying NCP seem crucial in this group of patients.**

Additionally we reported a significant correlation between low CD4 cell counts and risk of NCP. The association between CD4 cell count and cardiovascular disease has already

been previously reported and it may be related to immune-dysfunction (immune activation and immune senescence) or to the prevalence of other infection potentially affecting endothelial cells (cytomegalovirus, HHV-8, and others)<sup>38-40</sup>. **Similarly, previous studies reported a low CD4+ count to be associated with a high prevalence of carotid artery plaques<sup>41</sup>: our findings strengthen these observations supporting the hypothesis of a systemic inflammatory dysregulation in HIV-positive patients.**

The only other variable that showed a positive interaction on the risk of coronary stenosis was active smoking status, accordingly to the higher risk of smoker-related comorbidities previously reported in HIV-infected than uninfected patient. Notably, these subgroup are actually an attractive target for a “multi-disease” screening since that recent studies are currently investigating the role of CT for lung cancer prevention in HIV-positive smokers even if with sparse results<sup>42-44</sup>.

Clinical implications of present study may be of interest for physicians, cardiologists, infective disease specialists and general practitioners. **Plaque characteristics observed using CCT underline the vulnerable atherosclerotic pattern of HIV-positive subjects, suggesting the need of aggressive primary prevention programs in this specific population. These data highlight the importance of addressing modifiable cardiovascular risk factors to optimize long-term health in the setting of HIV infection comorbidities. Although not confirmed in randomized controlled trial, statins use may be crucial, for their effect on plaques stability. A parallel focus on smoking cessation is important, considering the interaction on the risk of coronary stenosis demonstrated from several studies. Furthermore several data report the underuse of aspirin in primary prevention<sup>45</sup> in high-risk HIV-positive patients despite heightened awareness regarding elevated cardiovascular risk, although the absence of randomized controlled trials may explain such conduct.**

Finally even if a CCT based approach for primary prevention has never been suggested to improve prognosis, these results may advise HIV physicians to evaluate and to focus on plaque characteristics in order to select appropriate primary prevention strategies.

## LIMITATIONS

Our study shares several limitations. Unfortunately it was not possible to report about long-term follow-up or hard clinical events in this population. Moreover we do not have detailed data about HAART regimen and almost all patients are male making it impossible to appraise specific differences. **Third, we reported incidence of coronary stenosis more than 30% considering our aim to focus on plaques' features independently from the percentage of stenosis.** Finally, the potential benefit by CCT needs to be weighted against its safety related to radiation exposure in asymptomatic young patients. Moreover as demonstrated in Table B, most of the included studies were of high quality, with an accurate definition of control population.

## CONCLUSION

In this comprehensive meta-analysis, NCP was more prevalent and extensive in asymptomatic HIV-infected patients, especially in presence of lower CD4 cell counts. **This finding provides new details on the differences in atherosclerotic process in HIV-infected patients, stressing the importance of primary prevention in this population. On the other hand the use of CCT may be considered in the future, if supported by larger prospective studies, as a complementary tool to evaluate high risk patients, both for traditional cardiovascular risk factors as well for severity of HIV infection.**

## REFERENCES.

- 1- Burgess MJ<sup>1</sup>, Kasten MJ. Human immunodeficiency virus: what primary care clinicians need to know. *Mayo Clin Proc.* 2013 Dec;88(12):1468-74.
- 2- Dabhadkar KC<sup>1</sup>, Bellam N Polypill strategy for primary prevention of cardiovascular disorders. *Drugs Today (Barc).* 2013 May;49(5):317-24
- 3- Burkholder GA<sup>1</sup>, Tamhane AR, Salinas JL, Mugavero MJ, Raper JL, Westfall AO, et al. of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. *Clin Infect Dis.* 2012 Dec;55(11):1550-7. Underutilization
- 4- Cerrato E, D'Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, et al. . Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. *Eur Heart J.* 2013 May;34(19):1432-6.
- 5- D'Ascenzo F<sup>1</sup>, Cerrato E<sup>2</sup>, Appleton D<sup>3</sup>, Moretti C<sup>1</sup>, Calcagno A<sup>4</sup>, Abouzaki N<sup>3</sup>, Vetrovec G<sup>3</sup>, Lhermusier T<sup>5</sup>, Carrie D<sup>6</sup>, Das Neves B<sup>7</sup>, Escaned J<sup>7</sup>, Cassese S<sup>8</sup>, Kastrati A<sup>8</sup>, Chinaglia A<sup>4</sup>, Belli R<sup>9</sup>, Capodanno D<sup>5</sup>, Tamburino C<sup>6</sup>, Santilli F<sup>10</sup>, Parodi G<sup>11</sup>, Vachiat A<sup>12</sup>, Manga P<sup>12</sup>, Vignali L<sup>13</sup>, Mancone M<sup>14</sup>, Sardella G<sup>14</sup>, Fedele F<sup>1</sup>, DiNicolantonio JJ<sup>15</sup>, Omedè P<sup>1</sup>, Bonora S<sup>16</sup>, Gaita F<sup>1</sup>, Abbate A<sup>17</sup>, Zoccai GB<sup>18</sup>; Percutaneous coronary intervention and surgical revascularization in HIV Database (PHD) Study Investigators Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute

- coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. *Thromb Res*. 2014 Sep;134(3):558-64. doi: 10.1016/j.thromres.2014.05.037. Epub 2014 Jun 2.
- 6- D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Moretti C, Omedè P, Sciuto F, et al Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. *Eur Heart J*. 2012 Apr;33(7):875-80
  - 7- Detrano R1, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *N Engl J Med*. 2008;358:1336-45.
  - 8- D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, Vetrovec GW, et al. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. *Atherosclerosis*. 2013 Jan;226(1):178-85.
  - 9- Stone GW1, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*. 2011 Jan 20;364(3):226-35.
  - 10- Ellims AH, Wong G, Weir JM, Lew P, Meikle PJ, Taylor AJ Plasma lipidomic analysis predicts non-calcified coronary artery plaque in asymptomatic patients at intermediate risk of coronary artery disease. *Eur Heart J Cardiovasc Imaging*. 2014 in press
  - 11- D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Omedè P, Sciuto F, Presutti DG, et al F. Coronary computed tomographic angiography for detection of coronary artery disease in patients presenting to the emergency department with chest pain: a meta-analysis of randomized clinical trials. *Eur Heart J Cardiovasc Imaging*. 2013 Aug;14(8):782-9
  - 12- Kamperidis V, de Graaf MA, Broersen A, Ahmed W, Sianos G, Delgado V, et al Prognostic value of aortic and mitral valve calcium detected by contrast cardiac computed tomography angiography in patients with suspicion of coronary artery disease. *Am J Cardiol*. 2014 Mar 1;113(5):772-8.
  - 13- Hsue PY1, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD.. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. *Circulation*. 2004;109:1603-8.
  - 14- Currier JS1, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, Li Y, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. *AIDS*. 2007;21:1137-45
  - 15- Grunfeld C1, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al.. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. *AIDS*. 2009;23:1841-9.
  - 16- Moher D, Liberati A, Tetzlaff J, Altman DG ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009 Jul 21;339:b2535. doi: 10.1136/bmj.b2535.
  - 17- Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF.; Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. *Lancet*. 1999 Nov 27;354(9193):1896-900.
  - 18- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al.; Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000 Apr 19;283(15):2008-12
  - 19- [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
  - 20- Post WS, Budoff M, Kingsley L, Palella FJ Jr, Witt MD, Li X, et al. Associations Between HIV Infection and Subclinical Coronary Atherosclerosis. *Ann Intern Med*. 2014 Apr 1;160(7):458-67. doi: 10.7326/M13-1754.
  - 21- D'Abramo A, D'Agostino C, Oliva A, Iannetta M, D'Ettorre G, Vullo F, et al Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. *ISRN AIDS*. 2013 Dec 5;2013:737083.
  - 22- Zanni MV1, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, Grinspoon SK. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. *AIDS*. 2013 May 15;27(8):1263-72. *AIDS*. 2012 Nov 28;26(18):2409-12.
  - 23- Pereyra F1, Lo J, Triant VA, Wei J, Buzon MJ, Fitch KV, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. *AIDS*. 2012 Nov 28;26(18):2409-12.
  - 24- Hwang JJ1, Wei J, Abbara S, Grinspoon SK, Lo J. Receptor activator of nuclear factor- $\kappa$ B ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. *J Acquir Immune Defic Syndr*. 2012 Nov 1;61(3):359-63.
  - 25- Duarte H1, Matta JR, Muldoon N, Masur H, Hadigan C, Gharib AM. Non-calcified coronary plaque volume inversely related to CD4(+) T-cell count in HIV infection. *Antivir Ther*. 2012;17(4):763-7.
  - 26- Burdo TH1, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. *J Infect Dis*. 2011 Oct 15;204(8):1227-36.
  - 27- Fitch KV1, Lo J, Abbara S, Ghoshhajra B, Shturman L, Soni A, et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. *J Acquir Immune Defic Syndr*. 2010 Dec;55(4):495-9.
  - 28- Lo J1, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, Nasir K, et al Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. *AIDS*. 2010 Jan 16;24(2):243-53.
  - 29- Maurovich-Horvat P1, Schlett CL, Alkadhi H, Nakano M, Stolzmann P, Vorpahl M, et al Differentiation of early from advanced coronary atherosclerotic lesions: systematic comparison of CT, intravascular US, and optical frequency domain imaging with histopathologic examination in ex vivo human hearts. *Radiology*. 2012 Nov;265(2):393-401.
  - 30- Motoyama S1, Kondo T, Sarai M, Sugiura A, Harigaya H, Sato T, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. *J Am Coll Cardiol*. 2007;50:319-26.
  - 31- Ahmadi N1, Nabavi V, Hajsadeghi F, Flores F, French WJ, Mao SS, et al. Mortality incidence of patients with non-obstructive coronary artery disease diagnosed by computed tomography angiography. *Am J Cardiol*. 2011;107:10-6.

- 32- Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*. 2011 Jan 20;364(3):226-35.
- 33- Virmani R., Burke A.P., Farb A., Kolodgie F.D.; Pathology of the vulnerable plaque. *J Am Coll Cardiol*. 47 2006:C13-C18.
- 34- Hausleiter J, Meyer T, Hadamitzky M, Kastrati A, Martinoff S, Schömig A. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. *J Am Coll Cardiol*. 2006 Jul 18;48(2):312-8.
- 35- Park GM, Lee SW, Cho YR, Kim CJ, Cho JS, Park MW, Her SH, Ahn JM, Lee JY, Park DW, Kang SJ, Kim YH, Lee CW, Koh EH, Lee WJ, Kim MS, Lee KU, Kang JW, Lim TH, Park SW, Park SJ, Park JY. Coronary computed tomographic angiographic findings in asymptomatic patients with type 2 diabetes mellitus. *Am J Cardiol*. 2014 Mar 1;113(5):765-71.
- 36- Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee SA, Nelson KE, Wu KC, Chen S, Tong W, Lai S. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. *Am Heart J*. 2002 Oct;144(4):642-8.
- 37- Talwani R, Falusi OM, Mendes de Leon CF, Nerad JL, Rich S, Proia LA, Sha BE, Smith KY, Kessler HA. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2002 Jun 1;30(2):191-5.
- 38- Sacre K, Hunt PW, Hsue PY, Maidji E, Martin JN, Deeks SG, et al. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. *AIDS*. 2012 Apr 24;26(7):805-14.
- 39- Steele AK, Lee EJ, Manuzak JA, Dillon SM, Beckham JD, et al. Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways Ex vivo. *Retrovirology*. 2014 Feb 4;11:14.
- 40- Zanni MV, Kelesidis T, Fitzgerald ML, Lo J, Abbara S, Wai B, et al. HDL redox activity is increased in HIV-infected men in association with macrophage activation and noncalcified coronary atherosclerotic plaque. *Antivir Ther*. 2014 Feb 17.
- 41- Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, Hodis HN. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. *AIDS*. 2008 Aug 20;22(13):1615-24.
- 42- Calvo-Sánchez M, Perelló R, Pérez I, et al. Differences between HIV-infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case-control studies. *HIV Med* 2013; 14:40–8.
- 43- Hulbert A, Hooker CM, Keruly JC, Brown T, Horton K, Fishman E, et al. Prospective CT Screening for Lung Cancer in a High-Risk Population: HIV-Positive Smokers. *J Thorac Oncol*. 2014 Jun;9(6):752-9.
- 44- Detrano R1, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *N Engl J Med*. 2008;358:1336-45
- 45- Burkholder GA, Tamhane AR, Salinas JL, Mugavero MJ, Raper JL, Westfall AO, et al. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. *Clin Infect Dis*. 2012 Dec;55(11):1550-7.